Amantadine
Adamantane Derivatives
- Drug class
- Adamantane Derivatives
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 20
Overview
Plain-language summary, compiled from the cited regulatory records
Amantadine is an antiviral medication belonging to the adamantane derivatives class [1]. It is approved for the prophylaxis and treatment of signs and symptoms associated with infections caused by various strains of the influenza A virus [1]. Additionally, amantadine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions [1].
The medication is used for chemoprophylaxis, meaning it can help prevent the signs and symptoms of influenza A virus infection [1]. While amantadine is available under several brand names, this information does not specify which ones are currently marketed [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 17 | May 15, 2026 |
| US United States | FDA | 3 | June 6, 2025 |
GBUnited Kingdom· MHRA
17 products
Uses
Parkinson's disease.
Herpes zoster:
It is recommended that Amantadine be given to elderly or debilitated patients in whom the physician suspects that a severe and painful rash could occur. Amantadine can significantly reduce the proportion of patients experiencing pain of long duration.
How to take
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Influenza A Prophylaxis Amantadine hydrochloride capsules, USP are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses.
Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules, USP are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness.
Drug interactions
Known interactions involving Amantadine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL427650010 · revised April 10, 2026
- [2]FDA DailyMed · 0f70c79a-92a4-4a… · revised June 6, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.